Key result
Inhibition of the renin-angiotensin-aldosterone system and plasminogen activator-inhibitor-1 can prevent progression and potentially induce regression of glomerulosclerosis.
Why the study?
This article explores the interaction between the renin-angiotensin-aldosterone system and plasminogen activator-inhibitor-1 and its potential significance in progressive renal disease pathogenesis and renal sclerosis remodeling.
Design
Review
Authors
Loading...
Does not support clinical use; leaves open translation of dual RAAS/PAI-1 inhibition to human glomerulosclerosis.
This review highlights the potential for regressing glomerulosclerosis through targeted inhibition of the renin-angiotensin-aldosterone system and its downstream effects on PAI-1 and extracellular matrix degradation.
Stoian et al. (2020) conducted a review in Glomerulosclerosis. Renin-angiotensin-aldosterone system inhibitors was evaluated. Inhibition of the renin-angiotensin-aldosterone system and plasminogen activator-inhibitor-1 can prevent progression and potentially induce regression of glomerulosclerosis.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: